Gemma English’s Post

🔬 Additional Indicators that Investor Confidence in Precision Diagnostics is coming back: 💰The recent $130 million Series D round raised by BillionToOne valuing the precision diagnostics company at over $1 billion, is further confirmation that investor confidence is returning to the sector following Tempus AI's successful IPO. 📍This round, led by Premji Invest and supported by new and existing investors, underscores a cautious optimism. 🔄 BillionToOne's promising annual recurring revenue of $125 million and its differentiated molecular counting technology position it well in the competitive diagnostics market. ⚠️ However, despite these positive signs, there remains a long way to go before returning to pre-downturn levels, and we may never see the frenzied valuations of the pandemic years. 👉 Investors are becoming more discerning, focusing on tangible execution and long-term profitability over speculative growth.

Jonathan Montagu, CEO of MassBio member HotSpot Therapeutics, Inc., writes on the #LifeSCiVC blog about hopes around an immuno-oncology spring this year, aligning with the emergence of #biotech from its own long winter. Jonathan points out that after the #lifesciences industry dove headfirst into I-O “to address the substantial need that still persists for many cancer patients with a range of tumor types,” much of the second-generation agents fell short. He writes about why he’s optimistic that new approaches have started to turn the tide. What are your thoughts on the I-O space right now? https://lnkd.in/eMh62Z8j #immunooncology #oncology #patientdriven

Pioneering precision oncology advances, Certis Oncology Solutions secures an impressive $10M in Series C, soaring their total funding to $42M! Reflecting on my recent conversation with a fellow healthcare innovator, this news exemplifies the potent impact AI is making in personalizing cancer treatment. Certis's commitment to harnessing patient-derived tumor models for tailored therapies not only ignites hope but also showcases the transformative power of AI in healthcare. Join me in celebrating their advancement—may their breakthroughs usher in a new era of certainty in oncology. As healthcare continues to evolve, let’s discuss how AI can further revolutionize our approach to treatment. #PrecisionOncology #AIHealthcare #InnovationInMedicine https://lnkd.in/ebP6rvX5

Great way for UACI and Tech Launch Arizona company, Reglagene to move into the new year! Learn more about how the funds will go toward completing the clinical development medicine for the treatment of brain cancers and more at the link below.

Leaving this here...Not the first company to publicly note their changes to R&D plans over past year due to the Inflation Reduction Act and likely not the last. “We've taken the decision to focus on the larger tumor agnostic opportunity as our first regulatory approval pathway and align the timing of accessing the cholangiocarcinoma opportunity to this,” Patel said. “The IRA favors accessing larger opportunities initially versus the conventional approach of speed to market with smaller indications,” the CEO added. “This clearly pushes out our investment on commercial readiness.” #inflationreductionact #marketaccess #pricing #innovation #oncology #unintendedconsequences

Reglagene is concluding 2023 on a high note, securing an oversubscribed funding round totaling $5.4M. As we step into 2024, our focus intensifies on preparing our lead asset for clinical trials. https://lnkd.in/dmz8qNvU #Biotech #Braincancer #oncology

For companies establishing a presence in a new territory, having a right-sized space is critical. “I wanted a space that would allow me some optionality—ideally not something that was going to lock me into an exact size for a long period of time, where we would run the risk of under- or over-calling our needs.” This need for flexibility, Davis notes, is common among early-stage companies like Akamis Bio. And these companies are finding what they need at CIC campuses. Clinical-stage oncology company Akamis Bio is on a mission to create transformative therapeutics for individuals with hard-to-treat cancers. When it was time to expand that mission, they chose CIC Cambridge to establish their footprint in the U.S.

New piece from my ZS colleagues on antibody-drug conjugates: original analysis on today’s ADC pipelines, hypotheses on why we’ve seen such robust dealmaking activity of late and—most importantly—ideas for how and where companies can push ADCs into the future.   Whether you’re looking to add an #ADC to your portfolio or already have an established position and want to increase your chance of success, the piece is worth a read. #oncology